Department of Gynecology, Ningbo No.6 Hospital, Ningbo, China.
J BUON. 2020 Mar-Apr;25(2):757-763.
To investigate the influence of neoadjuvant chemotherapy on the efficacy, clinical indicators, prognosis and neutrophil/lymphocyte ratio (NLR) of stage IB2-IIB cervical cancer.
120 cervical cancer patients were selected and randomly divided into the control group (n=60) and the observation group (n=60). The patients in the observation group were treated with neoadjuvant chemotherapy combined with surgery, while those in the control group received treatment with surgery alone. The serum tumor markers [matrix metalloproteinase-9 (MMP-9), carcino-embryonic antigen (CEA) and cancer antigen 125 (CA-125)], immunoglobulins (Igs) (IgA and IgM), T-lymphocyte subsets [cluster of differentiation (CD) 4+, CD8+ and CD4+/CD8+], NLR, quality of life, change in cancer-related fatigue degree and clinical efficacy were compared before and after treatment between the two groups.
The levels of MMP-9, CEA, CA-125, NLR, IgA, IgM, CD4+ CD8+, CD4+/CD8+ and Cancer Fatigue Scale (CFS) were decreased, while the World Health Organization Quality of Life Scale Brief (WHOQOL-BREF) score was increased in both groups after treatment, and the observation group exhibited more apparent changes in those levels than the control group (p<0.05). The effective rate was higher, but the incidence rates of postoperative lymphatic metastasis, vascular invasion, parametrial invasion and positive margin were lower in the observation group than those in the control group (p<0.05). The observation group had longer survival time than the control group (p<0.05).
Neoadjuvant chemotherapy can effectively lower the levels of serum tumor markers and NLR, reduce the metastasis rate of cancer cells and the degree of cancer-related fatigue after operation, improve the quality of life and prolong the survival time.
探讨新辅助化疗对 IB2 期至 IIB 期宫颈癌患者疗效、临床指标、预后及中性粒细胞/淋巴细胞比值（NLR）的影响。
选取 120 例宫颈癌患者，随机分为对照组（n=60）和观察组（n=60）。观察组患者采用新辅助化疗联合手术治疗，对照组患者采用单纯手术治疗。比较两组患者治疗前后血清肿瘤标志物[基质金属蛋白酶-9（MMP-9）、癌胚抗原（CEA）和糖类抗原 125（CA-125）]、免疫球蛋白（Igs）（IgA 和 IgM）、T 淋巴细胞亚群[分化群（CD）4+、CD8+和 CD4+/CD8+]、NLR、生活质量、癌因性疲乏程度变化及临床疗效。
两组患者治疗后 MMP-9、CEA、CA-125、NLR、IgA、IgM、CD4+CD8+、CD4+/CD8+及癌症疲乏量表（CFS）评分均降低，世界卫生组织生存质量测定量表简表（WHOQOL-BREF）评分升高，且观察组变化幅度大于对照组（p<0.05）。观察组患者有效率高于对照组，术后淋巴结转移、脉管侵犯、宫旁侵犯及切缘阳性发生率均低于对照组（p<0.05）。观察组患者生存时间长于对照组（p<0.05）。
新辅助化疗可有效降低患者血清肿瘤标志物及 NLR 水平，降低术后癌细胞转移率及癌因性疲乏程度，提高生活质量，延长生存时间。
